Special Issue "Pharmacological and Clinical Significance of Heme Oxygenase-1 2022"
A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".
Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 23738
Interests: obesity; diabetes; hypertension; cardiovascular disease; heme oxygenase; bilirubin; biliverdin reductase; antioxidants
Special Issues, Collections and Topics in MDPI journals
Special Issue in Livers: Hepatic Insulin Resistance and Whole-Body Outcomes
Special Issue in Biomedicines: Advanced Research in Heme Oxygenase
The Special Issue will continue to focus on the most up-to-date knowledge concerning the pharmacology and clinical applications of the enzyme heme oxygenase-1 (HO-1) that plays a critical role in the catabolism of heme to the bile pigment bilirubin, generating carbon monoxide (CO) and releasing iron, which is sequestered by ferritin.
This Special Issue will highlight the wealth of research on the hereditary and acquired disorders of heme metabolism and the role of dietary regulation of heme-containing proteins via hormonal and chemical actions as well as on the genetic and acquired disorders associated with such diseases as neonatal jaundice and hemochromatosis.
In recent years, the discovery of non-heme-containing inducers of HO-1 has resulted in new discoveries regarding the metabolic and cardiovascular effects of the upregulation of HO activity. This is especially relevant to a wide variety of natural product HO-1 inducers, which have the potential for important pharmaceutical and clinical applications, all of which will be highlighted in this Special Issue.
The HO-1 system plays an important role in cellular defense in the context of several diseases or physiological processes, including cardiovascular disease, diabetes, obesity, inflammation, neurodegeneration and ageing, and transplantation, among many others. The HO-derived metabolites CO and bilirubin also play an important physiological role and could be a source of clinical therapeutics for several diseases. CO-releasing molecules have potential therapeutic uses for vascular disease as well as obesity. Bilirubin has recently been discovered to have hormone-like functions that could be very beneficial for cardiovascular and metabolic diseases. The importance of the heme degradation pathway to pharmacology and clinical medicine has increased significantly over the past several years, with over 35,000 manuscripts published in this area.
This Special Issue will continue to highlight the diverse role that HO-1 and its metabolites play in numerous physiological functions and how this system can offer potential therapeutics for several diseases. We welcome submissions from a broad range of disciplines, which may highlight a novel function or therapeutic application of this important pathway.
Dr. David E. Stec
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.